1. Chen, Tian-Wei, Yin, Fen-Fen, Yuan, Yan-Mei, Li, Jing-Jing, Xie, Dong. 2019. CHML promotes liver cancer metastasis by facilitating Rab14 recycle. In Nature communications, 10, 2510. doi:10.1038/s41467-019-10364-0. https://pubmed.ncbi.nlm.nih.gov/31175290/
2. Dodson, Matthew, Dai, Wujing, Anandhan, Annadurai, Chapman, Eli, Zhang, Donna D. 2022. CHML is an NRF2 target gene that regulates mTOR function. In Molecular oncology, 16, 1714-1727. doi:10.1002/1878-0261.13194. https://pubmed.ncbi.nlm.nih.gov/35184380/
3. Dong, Changqing, Cao, Hui, Liu, Zhengcheng, Shi, Ye, Yang, Rusong. 2021. CHML targeted by miR-199a-3p promotes non-small cell lung cancer cell growth via binding to Rab5A. In Pathology, research and practice, 227, 153626. doi:10.1016/j.prp.2021.153626. https://pubmed.ncbi.nlm.nih.gov/34649053/
4. Zhang, Weilong, Cao, Ling, Liu, Xiaoni, Yuan, Xiaoliang, Jing, Hongmei. 2019. High expression of CHML predicts poor prognosis of multiple myeloma. In Journal of Cancer, 10, 6048-6056. doi:10.7150/jca.34465. https://pubmed.ncbi.nlm.nih.gov/31762814/
5. Changqing, Dong, Cao, Hui, Liu, Zhengcheng, Shi, Ye, Yang, Rusong. 2021. Corrigendum to 'CHML targeted by miR-199a-3p promotes non-small cell lung cancer cell growth via binding to Rab5A' [Pathol. Res. Pract. 2021 Nov;227-153626/PRP-D-21-01494R1 [211111-005370]. In Pathology, research and practice, 229, 153698. doi:10.1016/j.prp.2021.153698. https://pubmed.ncbi.nlm.nih.gov/34826741/
6. Zhan, Q, Xu, Z. . CHML suppresses cell growth and induces apoptosis in multiple human tumor lines. In Anticancer research, 19, 2893-9. doi:. https://pubmed.ncbi.nlm.nih.gov/10652570/
7. Chen, Xian-Cheng, Yu, Bo, Dong, Jing-Cheng, Varticovski, Lyuba, Wang, Xin Wei. . A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies. In Anticancer research, 27, 1593-600. doi:. https://pubmed.ncbi.nlm.nih.gov/17595781/
智鼠故事 
